Inhibitors of any of the targets, such as PARP, HER2, PI3K, AKT, mammalian target of rapamycin (mTOR), fibroblast growth factor (FGF) receptors (FGFRs), and vascular endothelial growth factor (VEGF), could potentially be used as therapeutic approaches to stop the progression of breast cancer due to their roles in various pathways of carcinogenesis, including the cell cycle, angiogenesis, metastasis, etc. [39, 40]. This evidence concerns the gene AKT1 and breast carcinoma.